Overview

Canakinumab for Treatment of Adult-onset Still's Disease

Status:
Terminated
Trial end date:
2018-05-05
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Treatments:
Antibodies, Monoclonal